Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

881 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S. Taniguchi H, et al. Among authors: uehara h. Nat Commun. 2019 Jan 16;10(1):259. doi: 10.1038/s41467-018-08074-0. Nat Commun. 2019. PMID: 30651547 Free PMC article.
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer.
Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. Okura N, et al. Among authors: uehara h. Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17. Clin Cancer Res. 2020. PMID: 31953310
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S. Wang R, et al. Among authors: uehara h. Nat Commun. 2020 Sep 14;11(1):4607. doi: 10.1038/s41467-020-18442-4. Nat Commun. 2020. PMID: 32929081 Free PMC article.
Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab.
Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise H, Sakiyama S, Nishioka Y. Mitsuhashi A, et al. Among authors: uehara h. Nat Commun. 2015 Dec 4;6:8792. doi: 10.1038/ncomms9792. Nat Commun. 2015. PMID: 26635184 Free PMC article.
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.
Tanimura K, Yamada T, Okada K, Nakai K, Horinaka M, Katayama Y, Morimoto K, Ogura Y, Takeda T, Shiotsu S, Ichikawa K, Watanabe S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Taniguchi H, Yoneda K, Matoba S, Sakai T, Uehara H, Yano S, Kusaba T, Katayama R, Takayama K. Tanimura K, et al. Among authors: uehara h. NPJ Precis Oncol. 2022 Jan 18;6(1):5. doi: 10.1038/s41698-021-00250-8. NPJ Precis Oncol. 2022. PMID: 35042943 Free PMC article.
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Yoshimura A, Yamada T, Serizawa M, Uehara H, Tanimura K, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Shukuya T, Nishiyama A, Goto Y, Shiotsu S, Kunimasa K, Morimoto K, Katayama Y, Suda K, Mitsudomi T, Yano S, Kenmotsu H, Takahashi T, Takayama K. Yoshimura A, et al. Among authors: uehara h. Cancer Sci. 2023 Feb;114(2):606-618. doi: 10.1111/cas.15608. Epub 2022 Nov 11. Cancer Sci. 2023. PMID: 36169649 Free PMC article.
881 results